ArticleKidney medicine2026
Clinical Features and Outcomes of Recurrent IgA Nephropathy After Transplantation: A Case Series and Comparison to Native Disease.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent IgA nephropathy (rIgAN) after kidney transplantation threatens long-term graft survival, yet contemporary clinicopathological descriptions are limited. We describe clinical, histological, and outcome features of rIgAN and compare them with native IgAN (nIgAN) in a single-center retrospective case series. Adults with biopsy-proven IgAN between 2010 and 2022 were included, comprising 21 adults with rIgAN and 63 with nIgAN. Demographic, clinical, and histopathological data, including Oxford MEST-C scores, were used, and patients were followed until kidney failure, death, or end of study. Patients with rIgAN were older at diagnosis and more frequently men. Kidney dysfunction at diagnosis was more advanced in rIgAN (creatinine was 227 μmol/L vs 128 μmol/L). Active inflammatory lesions mesangial and endocapillary hypercellularity were comparable between groups whereas chronic damage (segmental sclerosis and tubular atrophy) were more prevalent in rIgAN. Over follow-up, 52% of rIgAN patients progressed to kidney failure, with at a shorter median time (17 vs 50 months). Renal survival curves illustrated reduced graft survival in rIgAN. rIgAN was associated with a more aggressive clinical course and earlier graft failure. These findings underline the need for risk-adapted posttransplant surveillance and support evaluation of emerging nIgAN-directed therapies in the transplant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.